Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,471,610 papers from all fields of science
Search
Sign In
Create Free Account
ASA 404
Known as:
ASA-404
, ASA404
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
vadimezan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Nit-Picking around second line in EGFR NSCLC: just an academic effort
H. West
2015
Corpus ID: 14443735
1. Scagliotti GV, Bondarenko I, Blackhall F et al. Randomized, phase III trial of figitumumab in combination with erlotinib…
Expand
2014
2014
Differential TNF[alpha] and Toll-like-receptor 4-signaling in endocrine tumors after tumor- vascular- disrupting Agent ASA404 (Vadimezan) and TNF[alpha] treatment
C. Hantel
,
R. Lira
,
+4 authors
F. Beuschlein
2014
Corpus ID: 84013009
2012
2012
Preclinical Development Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma
L. Ellis
,
P. Shah
,
+5 authors
R. Pili
2012
Corpus ID: 7696030
Renal cell carcinoma (RCC) is an angiogenesis-dependent andhypoxia-drivenmalignancy.As a result, there has been an increased…
Expand
2011
2011
Abstract 677: Effects of the vascular disrupting agent ASA404 on tumor growth of gastric cancer in an experimental model
C. Moser
,
S. Lang
,
E. Jung
,
K. Pfister
,
E. Geissler
,
H. Schlitt
2011
Corpus ID: 75445928
Background: A functional vascular system is essential for growth of solid malignancies including gastric cancer. For…
Expand
2010
2010
Cancer Therapy : Clinical Phase 1 First-inHuman Trial of the Vascular Disrupting Agent Plinabulin ( NPI-2358 ) in Patients with Solid Tumors or Lymphomas
M. Mita
,
M. Spear
,
+13 authors
P. LoRusso
2010
Corpus ID: 30159627
Purpose: Plinabulin (NPI-2358) is a vascular disrupting agent that elicits tumor vascular endothelial architectural…
Expand
2010
2010
Plasma biomarker analysis of a phase I trial of ASA404 (vadimezan) in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer (NSCLC).
M. Shi
,
N. Funami
,
+7 authors
K. Kobayashi
2010
Corpus ID: 58652927
e18035 Background: ASA404 (vadimezan, DMXAA) is a flavonoid, non-tubulin-binding tumor-vascular disrupting agent (Tumor- VDA…
Expand
2010
2010
Anti-tumor activity of the tumor-vascular-disrupting agent ASA404 (vadimezan) in endocrine tumor models
C. Hantel
,
Roman Franzev
,
A. Ozimek
,
T. Mussack
,
F. Beuschlein
2010
Corpus ID: 68129004
2010
2010
ASA404 fails second late-stage lung cancer trial
S. Pal
2010
Corpus ID: 182520712
Novartis and its partner Antisoma announced that an interim analysis of data from a late-stage trial showed that vadimezam…
Expand
2008
2008
Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study
R. Pili
,
M. Rosenthal
2008
Corpus ID: 73827925
5007 Background: DMXAA (ASA404) is a novel tumor vascular disrupting agent. In animal models DMXAA has synergistic anti-tumor…
Expand
2008
2008
Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404)
M. McKeage
,
M. Jameson
2008
Corpus ID: 78438267
8072 Background: DMXAA (ASA404) is a tumor vascular disrupting agent recently evaluated in phase II trials in NSCLC. A randomized…
Expand